Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zenas BioPharma (ZBIO) EBITDA Margin (2023 - 2025)

Zenas BioPharma (ZBIO) has 2 years of EBITDA Margin data on record, last reported at 336.26% in Q1 2025.

  • For Q1 2025, EBITDA Margin changed N/A year-over-year to 336.26%; the TTM value through Sep 2025 reached 1266.82%, changed N/A, while the annual FY2024 figure was 3136.62%, 306253.0% down from the prior year.
  • EBITDA Margin reached 336.26% in Q1 2025 per ZBIO's latest filing, up from 1049.3% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 336.26% in Q1 2025 and bottomed at 1049.3% in Q4 2024.